Floatz logo

Adu-1805

NSCLC (Advanced Non-small Cell Lung Cancer)

Sairopa B.V.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

1205 Active assets in the NSCLC (Advanced Non-small Cell Lung Cancer) cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Adu-1805 is also rated in:

clear cell renal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
refractory malignant neoplasmDormant
C
Indicative ·
39 / 100
View asset →
Solid Tumor, AdultDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →